Cardiovascular Systems Company Profile (NASDAQ:CSII)

About Cardiovascular Systems (NASDAQ:CSII)

Cardiovascular Systems logoCardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee. Its products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral. The Company's coronary arterial disease (CAD) product, Diamondback 360 Coronary OAS (Coronary OAS), is marketed as a treatment for severely calcified coronary arteries.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment, Supplies & Distribution
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:CSII
  • CUSIP: 14161910
  • Web:
  • Market Cap: $911.56 million
  • Outstanding Shares: 32,991,000
Average Prices:
  • 50 Day Moving Avg: $29.97
  • 200 Day Moving Avg: $30.14
  • 52 Week Range: $21.29 - $33.11
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $204.91 million
  • Price / Sales: 4.43
  • Book Value: $3.60 per share
  • Price / Book: 7.64
  • EBIDTA: $5.43 million
  • Net Margins: -0.87%
  • Return on Equity: 0.88%
  • Return on Assets: 0.58%
  • Debt-to-Equity Ratio: 0.18%
  • Current Ratio: 3.88%
  • Quick Ratio: 3.47%
  • Average Volume: 242,875 shs.
  • Beta: 2.62
  • Short Ratio: 4.87

Frequently Asked Questions for Cardiovascular Systems (NASDAQ:CSII)

What is Cardiovascular Systems' stock symbol?

Cardiovascular Systems trades on the NASDAQ under the ticker symbol "CSII."

How were Cardiovascular Systems' earnings last quarter?

Cardiovascular Systems, Inc. (NASDAQ:CSII) posted its quarterly earnings results on Wednesday, August, 2nd. The company reported $0.02 EPS for the quarter, beating the Zacks' consensus estimate of ($0.05) by $0.07. The business earned $52.90 million during the quarter, compared to the consensus estimate of $51.98 million. Cardiovascular Systems had a positive return on equity of 0.88% and a negative net margin of 0.87%. Cardiovascular Systems's revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.15) earnings per share. View Cardiovascular Systems' Earnings History.

When will Cardiovascular Systems make its next earnings announcement?

Cardiovascular Systems is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for Cardiovascular Systems.

Where is Cardiovascular Systems' stock going? Where will Cardiovascular Systems' stock price be in 2017?

8 equities research analysts have issued 1 year price targets for Cardiovascular Systems' stock. Their forecasts range from $30.00 to $40.00. On average, they expect Cardiovascular Systems' stock price to reach $34.40 in the next year. View Analyst Ratings for Cardiovascular Systems.

What are analysts saying about Cardiovascular Systems stock?

Here are some recent quotes from research analysts about Cardiovascular Systems stock:

  • 1. According to Zacks Investment Research, "Cardiovascular Systems delivered remarkable fourth-quarter 2017 results, with earnings and revenues beating the Zacks Consensus Estimate. The company’s lower operating expenses drove the year-over-year improvement in earnings. Strong revenue performance also contributed to the upside in earnings. Moreover, the improvement in margins is encouraging. Overall, the company’s’ fiscal 2017 performance has been impressive. The company’s fiscal 2018 guidance also instils confidence in investors. It received FDA approval for radial access Diamondback 360 Peripheral Orbital Atherectomy Device. The one-year results from LIBERTY 360 study is to be presented at the 2017 Amputation Prevention Symposium (AMP). In the majority of the last six months, Cardiovascular Systems has been trading above the broader industry. However, the company incurred a net loss of $1.8 million in fiscal 2017. Stiff competition adds to the woes." (8/4/2017)
  • 2. Needham & Company LLC analysts commented, "We are reiterating our Buy rating on CSII, raising our FY18 and FY19 estimates, and raising our price target to $37 from $32. Over the next few quarters, we expect revenue growth to slow due to tougher comps but we expect earnings upside to drive shares higher. We expect the ECLIPSE trial and Japan to drive strong coronary growth in coming years." (7/14/2017)

Who are some of Cardiovascular Systems' key competitors?

Who are Cardiovascular Systems' key executives?

Cardiovascular Systems' management team includes the folowing people:

  • Scott R. Ward, Chairman of the Board, President, Chief Executive Officer
  • Laurence L. Betterley, Chief Financial Officer
  • Kevin J. Kenny, Chief Operating Officer
  • Sandra Sedo, Chief Compliance Officer
  • Alexander Rosenstein, General Counsel and Corporate Secretary
  • Martha Goldberg Aronson, Independent Director
  • Scott A. Bartos, Independent Director
  • Brent G. Blackey, Independent Director
  • Edward M. Brown, Independent Director
  • William E. Cohn M.D., Independent Director

Who owns Cardiovascular Systems stock?

Cardiovascular Systems' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.70%), Frontier Capital Management Co. LLC (2.51%), State Street Corp (2.07%), New York State Common Retirement Fund (1.35%), Northern Trust Corp (1.35%) and First Manhattan Co. (1.29%). Company insiders that own Cardiovascular Systems stock include Alexander Rosenstein, Camber Capital Management Llc, Edward M Brown, Kevin J Kenny, Laura Gillund, Laurence L Betterley, Paul A Koehn, Robert J Thatcher and Scott R Ward. View Institutional Ownership Trends for Cardiovascular Systems.

Who sold Cardiovascular Systems stock? Who is selling Cardiovascular Systems stock?

Cardiovascular Systems' stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co., Thrivent Financial For Lutherans, Perkins Capital Management Inc., EAM Investors LLC, Wells Fargo & Company MN, Arrowstreet Capital Limited Partnership, Acadian Asset Management LLC and Prudential Financial Inc.. Company insiders that have sold Cardiovascular Systems stock in the last year include Alexander Rosenstein, Edward M Brown, Kevin J Kenny, Laura Gillund, Laurence L Betterley, Paul A Koehn and Scott R Ward. View Insider Buying and Selling for Cardiovascular Systems.

Who bought Cardiovascular Systems stock? Who is buying Cardiovascular Systems stock?

Cardiovascular Systems' stock was bought by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Fred Alger Management Inc., Vanguard Group Inc., Marshall Wace North America L.P., Nationwide Fund Advisors, First Trust Advisors LP, Monarch Partners Asset Management LLC and TIAA CREF Investment Management LLC. Company insiders that have bought Cardiovascular Systems stock in the last two years include Camber Capital Management Llc and Scott R Ward. View Insider Buying and Selling for Cardiovascular Systems.

How do I buy Cardiovascular Systems stock?

Shares of Cardiovascular Systems can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cardiovascular Systems' stock price today?

One share of Cardiovascular Systems stock can currently be purchased for approximately $27.52.

MarketBeat Community Rating for Cardiovascular Systems (NASDAQ CSII)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  213 (Vote Outperform)
Underperform Votes:  131 (Vote Underperform)
Total Votes:  344
MarketBeat's community ratings are surveys of what our community members think about Cardiovascular Systems and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cardiovascular Systems (NASDAQ:CSII) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings, 4 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.63)
Consensus Price Target: $34.40 (25.00% upside)

Analysts' Ratings History for Cardiovascular Systems (NASDAQ:CSII)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/22/2017Raymond James Financial, Inc.Initiated CoverageMkt Perform -> Market PerformLowView Rating Details
9/21/2017Citigroup Inc.Initiated CoverageMarket PerformLowView Rating Details
7/14/2017Needham & Company LLCReiterated RatingBuy$32.00 -> $37.00HighView Rating Details
6/21/2017Bank of America CorporationDowngradeNeutral -> UnderperformLowView Rating Details
1/30/2017Lake Street CapitalInitiated CoverageBuy$40.00N/AView Rating Details
11/15/2016Leerink SwannReiterated RatingOutperform$30.00N/AView Rating Details
10/27/2016Feltl & Co.UpgradeBuy -> Strong-Buy$30.00N/AView Rating Details
10/7/2016JMP SecuritiesInitiated CoverageOutperform$35.00N/AView Rating Details
12/23/2015Northcoast ResearchInitiated CoverageBuy$18.00N/AView Rating Details
10/8/2015William BlairReiterated RatingOutperformN/AView Rating Details
10/8/2015Dougherty & CoLower Price TargetBuy$50.00 -> $32.00N/AView Rating Details
10/8/2015Benchmark Co.Lower Price TargetBuy$49.00 -> $20.00N/AView Rating Details
(Data available from 9/24/2015 forward)


Earnings History for Cardiovascular Systems (NASDAQ:CSII)
Earnings by Quarter for Cardiovascular Systems (NASDAQ:CSII)
Earnings History by Quarter for Cardiovascular Systems (NASDAQ CSII)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/24/2017N/AView Earnings Details
8/2/2017Q4 2017($0.05)$0.02$51.98 million$52.90 millionViewListenView Earnings Details
5/3/2017Q3 2017($0.05)($0.05)$51.13 million$52.10 millionViewListenView Earnings Details
1/25/2017Q217($0.06)$0.03$49.72 million$50.00 millionViewN/AView Earnings Details
10/26/2016Q117($0.18)($0.06)$205.50 million$49.80 millionViewListenView Earnings Details
8/3/2016Q416($0.20)($0.15)$46.01 million$48.50 millionViewN/AView Earnings Details
5/4/2016Q316($0.54)($0.31)$42.13 million$44.50 millionViewN/AView Earnings Details
1/21/2016Q216($0.50)($0.47)$44.82 million$41.40 millionViewListenView Earnings Details
11/4/2015Q116($0.42)($0.41)$43.90 million$43.90 millionViewN/AView Earnings Details
8/5/2015Q415($0.30)($0.27)$50.10 million$48.50 millionViewN/AView Earnings Details
4/29/2015Q315($0.33)($0.34)$46.84 million$47.00 millionViewListenView Earnings Details
1/28/2015Q215($0.34)($0.17)$43.97 million$44.70 millionViewListenView Earnings Details
10/29/2014Q115($0.33)($0.26)$40.24 million$41.40 millionViewListenView Earnings Details
8/6/2014Q214($0.28)($0.31)$37.21 million$39.56 millionViewListenView Earnings Details
4/30/2014Q114($0.32)($0.32)$34.15 million$34.90 millionViewListenView Earnings Details
1/29/2014Q2($0.34)($0.32)$30.62 million$32.30 millionViewListenView Earnings Details
8/7/2013Q4 2013($0.30)($0.28)$27.18 million$28.80 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Cardiovascular Systems (NASDAQ:CSII)
2017 EPS Consensus Estimate: ($0.45)
2018 EPS Consensus Estimate: $0.11
2019 EPS Consensus Estimate: $0.23
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($0.44)($0.14)($0.26)
Q2 20174($0.26)($0.05)($0.11)
Q3 20174($0.05)($0.02)($0.04)
Q4 20174($0.06)($0.02)($0.04)
Q1 20184($0.08)$0.00($0.02)
Q2 20184($0.01)$0.03$0.02
Q3 20183$0.04$0.05$0.04
Q4 20184$0.05$0.09$0.08
Q1 20191($0.02)($0.02)($0.02)
Q2 20191$0.04$0.04$0.04
Q3 20191$0.10$0.10$0.10
Q4 20191$0.11$0.11$0.11
(Data provided by Zacks Investment Research)


Dividend History for Cardiovascular Systems (NASDAQ:CSII)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Cardiovascular Systems (NASDAQ:CSII)
Insider Ownership Percentage: 3.60%
Institutional Ownership Percentage: 74.70%
Insider Trades by Quarter for Cardiovascular Systems (NASDAQ:CSII)
Institutional Ownership by Quarter for Cardiovascular Systems (NASDAQ:CSII)
Insider Trades by Quarter for Cardiovascular Systems (NASDAQ:CSII)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/31/2017Edward M BrownDirectorSell20,000$29.16$583,200.00View SEC Filing  
8/30/2017Edward M BrownDirectorSell13,031$29.09$379,071.79View SEC Filing  
8/17/2017Laura GillundInsiderSell2,350$30.42$71,487.00View SEC Filing  
8/17/2017Scott R WardCEOSell5,529$30.41$168,136.89View SEC Filing  
8/16/2017Alexander RosensteinGeneral CounselSell979$30.71$30,065.09View SEC Filing  
8/16/2017Kevin J KennyCOOSell4,733$30.74$145,492.42View SEC Filing  
8/16/2017Laurence L BetterleyCFOSell4,443$30.74$136,577.82View SEC Filing  
5/17/2017Alexander RosensteinGeneral CounselSell219$32.30$7,073.70View SEC Filing  
11/18/2016Alexander RosensteinGeneral CounselSell529$26.80$14,177.20View SEC Filing  
11/18/2016Edward M BrownDirectorSell10,000$26.78$267,800.00View SEC Filing  
11/18/2016Laura GillundInsiderSell1,268$26.79$33,969.72View SEC Filing  
11/15/2016Edward M BrownDirectorSell10,000$24.95$249,500.00View SEC Filing  
10/10/2016Paul A KoehnSVPSell30,910$25.07$774,913.70View SEC Filing  
9/20/2016Camber Capital Management LlcMajor ShareholderSell1,100,000$23.26$25,586,000.00View SEC Filing  
9/7/2016Paul A KoehnSVPSell5,969$25.02$149,344.38View SEC Filing  
8/22/2016Alexander RosensteinGeneral CounselSell234$23.82$5,573.88View SEC Filing  
8/22/2016Kevin J KennyCOOSell3,166$23.95$75,825.70View SEC Filing  
8/22/2016Laura GillundInsiderSell1,395$23.93$33,382.35View SEC Filing  
8/22/2016Laurence L BetterleyCFOSell3,568$23.96$85,489.28View SEC Filing  
8/22/2016Paul A KoehnSVPSell2,527$23.92$60,445.84View SEC Filing  
8/17/2016Paul A KoehnSVPSell4,000$22.17$88,680.00View SEC Filing  
2/26/2016Paul A KoehnSVPSell956$38.79$37,083.24View SEC Filing  
2/23/2016Camber Capital Management LlcMajor ShareholderBuy250,000$7.55$1,887,500.00View SEC Filing  
1/25/2016Scott R WardCEOBuy2,700$9.30$25,110.00View SEC Filing  
10/2/2015Robert J. ThatcherinsiderSell64,700$16.31$1,055,257.00View SEC Filing  
9/2/2015David MartinCEOSell19,646$23.81$467,771.26View SEC Filing  
9/1/2015Kevin J KennyCOOSell5,289$23.85$126,142.65View SEC Filing  
9/1/2015Laurence L BetterleyCFOSell9,597$23.96$229,944.12View SEC Filing  
9/1/2015Paul A KoehnSVPSell4,946$23.86$118,011.56View SEC Filing  
9/1/2015Robert J ThatcherInsiderSell5,282$23.85$125,975.70View SEC Filing  
8/18/2015David MartinCEOSell17,688$23.99$424,335.12View SEC Filing  
8/18/2015Kevin J. KennyCOOSell3,913$24.00$93,912.00View SEC Filing  
8/18/2015Laurence L BetterleyCFOSell8,476$24.00$203,424.00View SEC Filing  
8/18/2015Paul A. KoehnSVPSell4,402$23.99$105,603.98View SEC Filing  
8/18/2015Robert J. ThatcherinsiderSell2,960$23.99$71,010.40View SEC Filing  
8/12/2015Brent G BlackeyDirectorBuy2,500$22.74$56,850.00View SEC Filing  
5/28/2015Paul A KoehnSVPSell4,389$27.86$122,277.54View SEC Filing  
5/1/2015Brent G BlackeyDirectorBuy2,500$29.38$73,450.00View SEC Filing  
2/10/2015David MartinCEOSell7,500$35.85$268,875.00View SEC Filing  
2/5/2015David MartinCEOSell4,500$34.96$157,320.00View SEC Filing  
1/29/2015Kevin J KennyVPSell4,212$35.00$147,420.00View SEC Filing  
9/3/2014David MartinCEOSell10,248$28.85$295,654.80View SEC Filing  
9/3/2014Kevin J KennyVPSell3,528$28.85$101,782.80View SEC Filing  
9/3/2014Laurence L BetterleyCFOSell4,674$28.82$134,704.68View SEC Filing  
9/3/2014Paul A KoehnSVPSell2,612$28.85$75,356.20View SEC Filing  
9/3/2014Robert J ThatcherInsiderSell2,791$28.85$80,520.35View SEC Filing  
8/28/2014Paul A KoehnSVPSell1,315$28.82$37,898.30View SEC Filing  
8/22/2014David MartinCEOSell13,957$29.03$405,171.71View SEC Filing  
8/22/2014Kevin J KennyVPSell2,914$29.09$84,768.26View SEC Filing  
8/22/2014Laurence L BetterleyCFOSell6,578$29.02$190,893.56View SEC Filing  
8/22/2014Paul A KoehnSVPSell2,755$29.06$80,060.30View SEC Filing  
8/22/2014Robert J ThatcherInsiderSell3,225$29.06$93,718.50View SEC Filing  
8/19/2014David MartinCEOSell11,754$29.28$344,157.12View SEC Filing  
8/19/2014Kevin J KennyVPSell2,117$29.28$61,985.76View SEC Filing  
8/19/2014Laurence L BetterleyCFOSell5,725$29.28$167,628.00View SEC Filing  
8/19/2014Paul A KoehnSVPSell2,168$29.28$63,479.04View SEC Filing  
8/19/2014Robert J ThatcherInsiderSell2,537$29.28$74,283.36View SEC Filing  
7/16/2014David MartinCEOSell10,703$28.83$308,567.49View SEC Filing  
7/16/2014Kevin J KennyVPSell3,007$28.83$86,691.81View SEC Filing  
7/16/2014Laurence L BetterleyCFOSell3,984$28.83$114,858.72View SEC Filing  
7/16/2014Paul A KoehnSVPSell2,716$28.83$78,302.28View SEC Filing  
7/16/2014Robert J ThatcherInsiderSell2,939$28.83$84,731.37View SEC Filing  
4/25/2014Kevin KennyVPSell15,484$28.79$445,784.36View SEC Filing  
2/24/2014David MartinCEOSell29,200$37.31$1,089,452.00View SEC Filing  
2/20/2014Kevin KennyVPSell6,779$36.02$244,179.58View SEC Filing  
1/30/2014David MartinCEOSell50,000$35.12$1,756,000.00View SEC Filing  
1/30/2014Robert ThatcherVPSell35,139$35.06$1,231,973.34View SEC Filing  
11/22/2013Robert ThatcherVPSell22,384$32.82$734,642.88View SEC Filing  
10/31/2013James E FlahertyInsiderSell34,819$30.35$1,056,756.65View SEC Filing  
10/23/2013David MartinCEOSell154,080$27.73$4,272,638.40View SEC Filing  
10/23/2013James E FlahertyInsiderSell36,682$26.85$984,911.70View SEC Filing  
10/23/2013Robert J ThatcherVPSell23,426$28.19$660,378.94View SEC Filing  
10/22/2013Kevin J KennyVPSell5,608$27.31$153,154.48View SEC Filing  
10/16/2013Kevin J KennyVPSell4,182$22.95$95,976.90View SEC Filing  
10/14/2013David MartinCEOSell21,170$22.00$465,740.00View SEC Filing  
9/20/2013David MartinCEOSell6,702$20.24$135,648.48View SEC Filing  
9/20/2013James FlahertyInsiderSell2,066$20.28$41,898.48View SEC Filing  
9/20/2013Robert ThatcherVPSell1,274$20.28$25,836.72View SEC Filing  
9/19/2013Laurence BetterleyCFOSell2,694$20.32$54,742.08View SEC Filing  
9/19/2013Paul KoehnSVPSell1,094$20.32$22,230.08View SEC Filing  
9/18/2013David MartinCEOSell8,030$20.94$168,148.20View SEC Filing  
9/18/2013James FlahertyInsiderSell2,970$20.94$62,191.80View SEC Filing  
9/18/2013Laurence BetterleyCFOSell4,324$20.93$90,501.32View SEC Filing  
9/18/2013Paul KoehnSVPSell1,732$20.93$36,250.76View SEC Filing  
9/18/2013Robert ThatcherVPSell1,731$20.94$36,247.14View SEC Filing  
9/10/2013John FriedmanDirectorSell48,273$20.73$1,000,699.29View SEC Filing  
8/30/2013David MartinCEOSell21,552$20.64$444,833.28View SEC Filing  
8/30/2013James FlahertyInsiderSell7,165$20.64$147,885.60View SEC Filing  
8/30/2013Kevin KennyVPSell1,899$20.64$39,195.36View SEC Filing  
8/30/2013Laurence BetterleyCFOSell8,692$20.64$179,402.88View SEC Filing  
8/27/2013David MartinCEOSell27,229$21.07$573,715.03View SEC Filing  
8/27/2013James FlahertyInsiderSell9,051$21.07$190,704.57View SEC Filing  
8/27/2013Kevin KennyVPSell2,396$21.07$50,483.72View SEC Filing  
8/27/2013Laurence BetterleyCFOSell10,982$21.07$231,390.74View SEC Filing  
8/16/2013James FlahertyInsiderSell1,255$20.51$25,740.05View SEC Filing  
8/16/2013Laurence BetterleyCFOSell1,568$20.51$32,159.68View SEC Filing  
8/14/2013James FlahertyInsiderSell4,902$21.31$104,461.62View SEC Filing  
8/13/2013Kevin KennyVPSell2,529$21.20$53,614.80View SEC Filing  
8/8/2013James FlahertyInsiderSell19,649$22.27$437,583.23View SEC Filing  
7/30/2013David MartinCEOSell11,094$19.69$218,440.86View SEC Filing  
7/30/2013Laurence L BetterleyCFOSell6,579$19.72$129,737.88View SEC Filing  
7/30/2013Robert J ThatcherVPSell3,112$19.86$61,804.32View SEC Filing  
6/3/2013James E FlahertyInsiderSell10,000$21.00$210,000.00View SEC Filing  
5/31/2013Paul A KoehnVPSell2,472$20.00$49,440.00View SEC Filing  
5/28/2013Kevin J KennyVPSell4,182$19.95$83,430.90View SEC Filing  
5/20/2013Glen D NelsonDirectorBuy10,250$18.47$189,317.50View SEC Filing  
5/16/2013Glen D NelsonDirectorBuy4,753$18.93$89,974.29View SEC Filing  
5/13/2013Glen D NelsonDirectorBuy18,393$18.11$333,097.23View SEC Filing  
11/13/2012Glen D NelsonDirectorBuy33,000$11.96$394,680.00View SEC Filing  
8/23/2012David MartinCEOSell10,510$9.07$95,325.70View SEC Filing  
8/23/2012James E FlahertyInsiderSell4,018$9.07$36,443.26View SEC Filing  
8/23/2012Laurence L BetterleyCFOSell4,770$9.07$43,263.90View SEC Filing  
8/23/2012Paul A KoehnVPSell2,496$9.07$22,638.72View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Cardiovascular Systems (NASDAQ:CSII)
Latest Headlines for Cardiovascular Systems (NASDAQ:CSII)
DateHeadline logoCardiovascular Systems, Inc. (CSII) Receives New Coverage from Analysts at Raymond James Financial, Inc. - September 22 at 9:18 AM logoCardiovascular Systems, Inc. (CSII) Earns Market Perform Rating from Analysts at Citigroup Inc. - September 21 at 5:38 PM logoLeerink Swann Equities Analysts Lower Earnings Estimates for Cardiovascular Systems, Inc. (CSII) - September 20 at 9:22 AM logoWill Hurricanes Choke Cardiovascular (CSII) Q1 Performance? - Nasdaq - September 19 at 5:35 PM logoCardiovascular Systems, Inc. (CSII) Forecasted to Post Q2 2018 Earnings of ($0.01) Per Share - September 19 at 9:24 AM logoCardiovascular Systems Announces Anticipated Revenue Impact ... - Business Wire (press release) - September 18 at 10:36 PM logoCardiovascular Systems suffers a hurricane hangover - September 18 at 5:34 PM logoCSII Crosses Below Key Moving Average Level - September 18 at 5:34 PM logoCommit To Purchase Cardiovascular Systems At $25, Earn 10.4% Annualized Using Options - September 14 at 6:25 PM logoCardiovascular Systems (CSII) Presents At Lake Street Capital Best Ideas Growth Conference - Slideshow - September 14 at 6:25 PM logoCardiovascular Systems (CSII) Down 3.5% Since Earnings Report: Can It Rebound? - Nasdaq - September 9 at 5:14 PM logoCardiovascular Systems (CSII) Down 3.5% Since Earnings Report: Can It Rebound? - September 8 at 5:59 PM logoCardiovascular Systems (CSII) Catches Eye: Stock Jumps 6.9% - September 5 at 7:10 PM logoCardiovascular Systems, Inc. breached its 50 day moving average in a Bullish Manner : CSII-US : September 5, 2017 - September 5 at 7:10 PM logo$53.41 Million in Sales Expected for Cardiovascular Systems, Inc. (CSII) This Quarter - September 5 at 1:56 AM logoZacks: Analysts Anticipate Cardiovascular Systems, Inc. (CSII) Will Post Earnings of -$0.07 Per Share - September 3 at 8:28 PM logoCardiovascular Systems, Inc. (CSII) Given Consensus Recommendation of "Hold" by Analysts - September 2 at 4:40 AM logoEdward M. Brown Sells 13,031 Shares of Cardiovascular Systems, Inc. (CSII) Stock - September 1 at 7:42 PM logoEdward M. Brown Sells 20,000 Shares of Cardiovascular Systems, Inc. (CSII) Stock - September 1 at 7:40 PM logoETFs with exposure to Cardiovascular Systems, Inc. : August 31, 2017 - August 31 at 10:32 PM logoCardiovascular Systems, Inc. :CSII-US: Earnings Analysis: 2017 By the Numbers : August 28, 2017 - August 28 at 5:24 PM logoNotable Two Hundred Day Moving Average Cross - CSII - August 25 at 9:43 PM logoCardiovascular Systems (CSII) Presents At CFA Society Of Minnesota 6th Annual Intellisight Conference - Slideshow - August 23 at 7:11 PM logoHaeggquist & Eck Investigates Cardiovascular Systems Inc. for ... - Business Wire (press release) - August 22 at 11:11 PM logoHaeggquist & Eck Investigates Cardiovascular Systems Inc. for Paying Illegal Kickbacks, Promoting Its Devices for Off-Label Purposes, and Violating FDA Laws and Regulations - August 22 at 11:11 PM logoCardiovascular Systems, Inc. (CSII) Insider Laura Gillund Sells 2,350 Shares - August 21 at 8:10 PM logoCardiovascular Systems, Inc. (CSII) CEO Sells $168,136.89 in Stock - August 21 at 7:46 PM logoCardiovascular Systems, Inc. (CSII) Downgraded to "Strong Sell" at BidaskClub - August 19 at 12:24 PM logoCardiovascular Systems, Inc. (CSII) Expected to Post Quarterly Sales of $53.41 Million - August 18 at 3:30 PM logoInsider Selling: Cardiovascular Systems, Inc. (CSII) General Counsel Sells 979 Shares of Stock - August 17 at 8:52 PM logoInsider Selling: Cardiovascular Systems, Inc. (CSII) CFO Sells 4,443 Shares of Stock - August 17 at 8:32 PM logoInsider Selling: Cardiovascular Systems, Inc. (CSII) COO Sells 4,733 Shares of Stock - August 17 at 8:32 PM logoCardiovascular Systems Unveils Favorable LIBERTY 360 Data - August 15 at 6:18 PM logoCardiovascular Systems, Inc. – Value Analysis (NASDAQ:CSII) : August 15, 2017 - August 15 at 6:18 PM logoLIBERTY 360° Study 12-Month Sub-Analysis Reveals High Freedom from Major Amputation and Major Adverse Events ... - Business Wire (press release) - August 12 at 5:01 PM logoLIBERTY 360° Study 12-Month Sub-Analysis Reveals High Freedom from Major Amputation and Major Adverse Events (MAE) Using Cardiovascular Systems’ Diamondback 360 ... - August 10 at 6:49 PM logoA new sub-analysis from the landmark LIBERTY 360° study, sponsored by Cardiovascular Systems, Inc. - August 10 at 6:49 PM logoLIBERTY 360° Study 12-Month Data Demonstrate Lasting Benefits Following Endovascular Intervention in Patients with Critical Limb Ischemia (CLI) - August 10 at 6:49 PM logoLIBERTY 360° Study 12-Month Sub-Analysis Reveals High Freedom from Major Amputation and Major Adverse Events (MAE) Using Cardiovascular Systems’ Diamondback 360® Peripheral Orbital Atherectomy System (OAS) - August 10 at 6:48 PM logoCardiovascular Systems, Inc. (NASDAQ:CSII) Receives Consensus Recommendation of "Hold" from Analysts - August 8 at 7:34 AM logoEquities Analysts Issue Forecasts for Cardiovascular Systems, Inc.'s Q1 2018 Earnings (NASDAQ:CSII) - August 7 at 7:58 AM logoCardiovascular Systems, Inc. (CSII) Cut to "Sell" at Zacks Investment Research - August 6 at 5:44 PM logoNorthcoast Research Weighs in on Cardiovascular Systems, Inc.'s FY2018 Earnings (CSII) - August 4 at 6:02 PM logoQ2 2018 Earnings Estimate for Cardiovascular Systems, Inc. (CSII) Issued By Leerink Swann - August 4 at 4:54 PM logoCardiovascular Systems' (CSII) CEO Scott Ward on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha - August 4 at 12:00 AM logoCardiovascular Systems, Inc. (NASDAQ:CSII) Announces Quarterly Earnings Results - August 3 at 8:32 PM logoEdited Transcript of CSII earnings conference call or presentation 2-Aug-17 8:45pm GMT - August 3 at 6:59 PM logoCardiovascular Systems, Inc. breached its 50 day moving average in a Bearish Manner : CSII-US : August 2, 2017 - August 2 at 11:24 PM logoCardiovascular Systems beats 4Q profit forecasts - August 2 at 11:24 PM logoCardiovascular Systems, Inc. Reports Fiscal 2017 Fourth-Quarter Financial Results - Business Wire (press release) - August 2 at 6:21 PM



Cardiovascular Systems (CSII) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by Staff